PATENT CLAIM ANALYSIS

Application Number: 15907505
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["424", "133100"]

Abstract:
The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.

Claim (Index 40):
The method of  claim 35 , wherein treatment results in partial elimination of the cancer or the metastasis thereof, total elimination of the cancer or the metastasis thereof, prolongation of survival of the subject, or a combination thereof.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 88.0
- Lexical Diversity: 2.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13485702', '14054446', '15337113', '12751907', '14838006']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8623324472356029
- 35 USC 102 Novelty (BERT): 0.567022739454487
- Combined Prediction Score: 0.8328014764574913
- Mean Citation Score: 697.3074919999997
- Max Citation Score: 742.2861
- Similarity Product: 351.95042082240883

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test